MX2012015102A - Agentes terapeuticos 976. - Google Patents

Agentes terapeuticos 976.

Info

Publication number
MX2012015102A
MX2012015102A MX2012015102A MX2012015102A MX2012015102A MX 2012015102 A MX2012015102 A MX 2012015102A MX 2012015102 A MX2012015102 A MX 2012015102A MX 2012015102 A MX2012015102 A MX 2012015102A MX 2012015102 A MX2012015102 A MX 2012015102A
Authority
MX
Mexico
Prior art keywords
therapeutic agents
azetidinyl
compound
melanin
prophylaxis
Prior art date
Application number
MX2012015102A
Other languages
English (en)
Inventor
Lanna Li
Lars Anders Mikael Johansson
Susanne Doris Margit Boekman-Winiwarter
Marlene Fredenwall
Carl Anders Hogner
Robert Andrew Judkins
Bjoern Christian Ingvar Loefberg
Sverker Vonunge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012015102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2012015102A publication Critical patent/MX2012015102A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen en la presente los compuestos de azetidinilo de la formula (I), según se describió en la presente las composiciones farmacéuticas que comprenden un compuesto de azetidinilo y. un método para el uso de un compuesto azetidinilo en el tratamiento e profilaxis de una enfermedad o condición relacionada son le hormona do concentración de melanina.
MX2012015102A 2010-07-06 2011-07-04 Agentes terapeuticos 976. MX2012015102A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36158510P 2010-07-06 2010-07-06
PCT/GB2011/051256 WO2012004588A2 (en) 2010-07-06 2011-07-04 Therapeutic agents 976

Publications (1)

Publication Number Publication Date
MX2012015102A true MX2012015102A (es) 2013-05-01

Family

ID=44514822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015102A MX2012015102A (es) 2010-07-06 2011-07-04 Agentes terapeuticos 976.

Country Status (26)

Country Link
US (1) US8546375B2 (es)
EP (1) EP2590969B1 (es)
JP (1) JP5827683B2 (es)
KR (1) KR20130041177A (es)
CN (1) CN103209979B (es)
AR (1) AR082113A1 (es)
AU (1) AU2011275547B2 (es)
BR (1) BR112013000296A2 (es)
CA (1) CA2802832A1 (es)
CL (1) CL2013000027A1 (es)
CR (1) CR20130005A (es)
CU (1) CU20130004A7 (es)
DO (1) DOP2013000004A (es)
EA (1) EA201291384A1 (es)
EC (1) ECSP13012369A (es)
ES (1) ES2527466T3 (es)
GT (1) GT201300006A (es)
MX (1) MX2012015102A (es)
NI (1) NI201200196A (es)
PE (1) PE20130781A1 (es)
PH (1) PH12013500027A1 (es)
SA (1) SA111320581B1 (es)
SG (1) SG186275A1 (es)
TW (1) TW201206916A (es)
UY (1) UY33487A (es)
WO (1) WO2012004588A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN104974106B (zh) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法
CN108840812B (zh) * 2018-06-29 2020-08-18 南京富润凯德生物医药有限公司 一种3-(二氟甲基)-3-羟基氮杂环丁烷中间体及其盐的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4212867A (en) * 1977-03-03 1980-07-15 Philagro 2-Cyano-5-substituted 1,3,4-oxadiazoles and fungicidal compositions containing them
DE3039087A1 (de) 1980-10-16 1982-05-19 Hoechst Ag, 6000 Frankfurt 1-(1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
GB2184122B (en) 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JPH07502529A (ja) 1991-12-31 1995-03-16 藤沢薬品工業株式会社 アセチルコリンエステラーゼ阻害およびムスカリン様のアゴニスト活性を有するオキサジアゾール誘導体
CA2201478A1 (en) 1995-08-02 1997-02-13 J. Uriach & Cia S.A. New carboxamides with antifungal activity
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
DE60329513D1 (de) 2002-07-30 2009-11-12 Banyu Pharma Co Ltd Antagonist des melanin-concentrating-hormone-rezeptors, enthaltend ein benzimidazolderivat als wirkstoff
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
JP2007517868A (ja) 2004-01-07 2007-07-05 アストラゼネカ アクチボラグ 治療薬ｉ
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
JP4982367B2 (ja) 2004-07-26 2012-07-25 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体薬剤としてのオキサゾール誘導体、製造及び治療的使用
US7846950B2 (en) 2004-10-18 2010-12-07 Eli Lilly And Company Histamine H3 receptor inhibitors, preparation and therapeutic uses
CN101072775A (zh) 2004-12-17 2007-11-14 伊莱利利公司 新的mch受体拮抗剂
WO2006068594A1 (en) 2004-12-21 2006-06-29 Astrazeneca Ab HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
MX2007014464A (es) 2005-05-31 2008-02-07 Astrazeneca Ab Antagonistas novedosos de mchr1 y sus usos para tratamiento de padecimientos y trastornos mediados por mchr1.
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
DE602006018301D1 (de) * 2005-06-22 2010-12-30 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US20080221107A1 (en) 2005-07-15 2008-09-11 Astrazeneca Ab Therapeutic Agents
UY30079A1 (es) 2006-01-06 2007-08-31 Astrazeneca Ab Compuestos
US7666888B2 (en) 2006-07-20 2010-02-23 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
JP2010501553A (ja) 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体
EP2102208B1 (en) 2006-12-05 2014-04-23 Janssen Pharmaceutica NV Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
KR20090082484A (ko) * 2006-12-14 2009-07-30 일라이 릴리 앤드 캄파니 5-[4-(아제티딘-3-일옥시)-페닐]-2-페닐-5ｈ-티아졸로[5,4-ｃ]피리딘-4-온 유도체 및 ｍｃｈ 수용체 길항제로서의 이들의 용도
WO2008131103A2 (en) 2007-04-17 2008-10-30 Vertex Pharmaceuticals Incorporated Drug discovery methods for aurora kinase inhibitors
AR067762A1 (es) 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
ATE519738T1 (de) 2007-08-22 2011-08-15 Hoffmann La Roche Pyrrolidinarylether als nk3-rezeptorantagonisten
PL2212283T3 (pl) * 2007-10-17 2012-01-31 Sanofi Sa Podstawione karboksyamidy N-fenylobipirolidyny i ich zastosowanie terapeutyczne
US8124636B2 (en) 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
EP2300422B1 (en) * 2008-05-08 2014-11-05 Evotec AG Azetidines as histamine h3 receptor antagonists
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
WO2011019090A1 (en) 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers

Also Published As

Publication number Publication date
PE20130781A1 (es) 2013-07-20
ECSP13012369A (es) 2013-01-31
UY33487A (es) 2012-02-29
SG186275A1 (en) 2013-01-30
KR20130041177A (ko) 2013-04-24
SA111320581B1 (ar) 2014-06-17
NI201200196A (es) 2013-10-16
EA201291384A1 (ru) 2013-07-30
CA2802832A1 (en) 2012-01-12
HK1182712A1 (en) 2013-12-06
CU20130004A7 (es) 2013-05-31
WO2012004588A2 (en) 2012-01-12
AU2011275547B2 (en) 2015-10-29
AR082113A1 (es) 2012-11-14
GT201300006A (es) 2014-11-06
JP5827683B2 (ja) 2015-12-02
DOP2013000004A (es) 2013-04-30
BR112013000296A2 (pt) 2019-09-24
WO2012004588A3 (en) 2012-08-09
AU2011275547A1 (en) 2013-02-07
CN103209979B (zh) 2016-02-10
CL2013000027A1 (es) 2013-03-08
ES2527466T3 (es) 2015-01-26
TW201206916A (en) 2012-02-16
CN103209979A (zh) 2013-07-17
PH12013500027A1 (en) 2017-10-25
CR20130005A (es) 2013-04-17
US20120010189A1 (en) 2012-01-12
EP2590969A2 (en) 2013-05-15
US8546375B2 (en) 2013-10-01
EP2590969B1 (en) 2014-10-15
JP2013535413A (ja) 2013-09-12

Similar Documents

Publication Publication Date Title
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
PH12012500620A1 (en) Compounds
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
PH12014500386A1 (en) Combination treatment for hepatitis c
IN2015DN01156A (es)
TN2011000172A1 (en) Therapeutic antiviral peptides
MY198204A (en) Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof
MX2011012122A (es) Derivados de tiofeno.
IN2012DN00971A (es)
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
GB201213267D0 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
WO2013040227A3 (en) Therapeutic compounds
PH12013500559A1 (en) Combination therapy for treating hcv infection
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX2011011618A (es) Agentes terapeuticos 713.
PH12013500027A1 (en) Therapeutic agents 976
MX355388B (es) Composiciones farmaceuticas y metodos terapeuticos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto.

Legal Events

Date Code Title Description
FG Grant or registration